Table 1 Development of symptomatology during CBD treatment

From: Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depressionCannabidiol-Therapie eines Jugendlichen mit multiplem Substanzabusus, Sozialphobie und Depression

  T1 (baseline) T2 (4 week follow-up) T3 (8 week follow-up)
  Before CBD onset After stopping sertraline Stable CBD treatmenta
Depressive Symptoms
Raw scores (cut-off label) of the BDI-IIb 22
(Moderate depressive episode)
10
(Minimal depressive episode)
7
(Minimal depressive episode)
Anxiety Symptoms
Raw scores (T values) of the German FSSC‑Rb 52 (60) 31 (50)
Fear of Danger and Deathb 7 (50) 4 (45)
Fear of Separation 5 (45) 4 (45)
Social Anxietyb 13 (70) 7 (60)
Fear of the Unknownb 13 (70) 9 (60)
Fear of Animals 2 (50) 3 (55)
Medical Fearsb 7 (65) 3 (50)
Fear of Evaluation and School Anxietyb 5 (55) 1 (45)
At-risk mental state
Raw scores of the ERIraosb 12 4
Mental disorder b (affective symptoms, withdrawal, school and sleep problems) 4 0
At-risk psychosis b (rumination, social insecurity, paranoia, special interests, tension) 5 2
Beginning psychosis (depersonalisation, derealisation, symptoms of schizophrenia) 3 2
  1. aStable medication with CBD, no other psychopharmacological treatment applied
  2. bShow clinically relevant improvement